Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SYK | P43405 | 1/20 | 0.47 |
| ▸ | DRD1 | P21728 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | DRD5 | P21918 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6034267 | 0.87 | LTA4H (0.52) | KDM4ETSHRALDH1A1HTTDRD1 | |
| SCHEMBL6595968 | 0.83 | SIGMAR1 (0.42) | KDM4EALDH1A1MAPT | |
| SCHEMBL31539648 | 0.82 | ALDH1A1 (0.59) | POLBKDM4ETSHRALDH1A1MAPT | |
| SCHEMBL2671540 | 0.82 | ALDH1A1 (0.62) | POLBKDM4ETSHRALDH1A1MAPT | |
| SCHEMBL538618 | 0.79 | ALDH1A1 (0.60) | KDM4ETSHRALDH1A1 | |
| SCHEMBL6035299 | 0.79 | HTR1B (0.47) | POLBKDM4EALDH1A1MAPTHTT | |
| SCHEMBL573096 | 0.78 | CYP1A2 (0.56) | POLBKDM4ETSHRALDH1A1MAPT | |
| SCHEMBL25379830 | 0.77 | POLB (0.49) | POLBKDM4ETSHRALDH1A1MAPT | |
| SCHEMBL13855801 | 0.76 | POLB (0.59) | POLBKDM4ETSHRALDH1A1SYK | |
| SCHEMBL2718979 | 0.76 | KDM4E (0.57) | POLBKDM4ETSHRALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060052396-A1 | Arylamines for the treatment of conditions associated with gsk-3 | ASTRAZENECA (SE) | 2006-03-09 | — | — | US | claimed |
| EP-1414801-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | AstraZeneca AB (SE) | 2004-05-06 | — | — | EP | claimed |
| WO-2003004472-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | WO | claimed |
| US-20060052396-A1 | Arylamines for the treatment of conditions associated with gsk-3 | ASTRAZENECA (SE) | 2006-03-09 | — | — | US | disclosed |
| EP-1414801-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | AstraZeneca AB (SE) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003004472-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052396-A1 | Arylamines for the treatment of conditions associated with gsk-3 | GSK3A, GSK3B, PYGL | POLB 2675/4885KDM4E 1319/4885TSHR 898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.